Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampligen after FOLFIRINOX for locally advanced pancreatic adenocarcinoma
NL-OMON59201Phase 2Not yet recruiting
- Sponsor
- AIM ImmunoTech
- Start
- Aug 2027
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rintatolimod in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by AIM ImmunoTech. Primary endpoint: Progression-free survival. Planned start Aug 2027; status: not yet recruiting.
02
Drugs
rintatolimod
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON59201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59201.